Amneal Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Amneal Pharmaceuticals (Bridgewater, NJ): 39 reconciled FDA prescription therapies (37.8% 2025 to 2030 cliff risk), $735.6M 2024 CMS Part D & Medicaid spend, and 32 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Bridgewater, NJ |
| Reconciled FDA Portfolio Therapies | 39 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 37.8% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $735.6M |
| 2024 Medicare Part D Spend | $527.6M |
| 2024 Medicaid Spend | $208.0M |
| California HCAI SB 17 Filings | 32 WAC filings (max 125.0% 2-yr change) |